aducanumab

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials Cambridge, March…

6 years ago

Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

Data Includes Additional Analyses of Long-Term Extension Phase 1b Study With Titration Cohort at 36 Months and Fixed-Dose Cohorts at…

6 years ago

Latest Data on Eisai’s Alzheimer’s Disease / Dementia Pipeline to be Presented at Alzheimer’s Association International Conference (AAIC) 2018

Thirteen presentations to be given including on Phase II study results of BAN2401 and elenbecestat Tokyo, July 23, 2018: Eisai…

6 years ago